Vijay Ramakrishnan, PhD

  • 352 Citations
  • 9 Scopus h-Index
20102019

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Vijay Ramakrishnan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 3 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

  • 352 Citations
  • 9 Scopus h-Index
  • 13 Article
  • 2 Review article

Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma

Ramakrishnan, V. G., Miller, K. C., Macon, E. P., Kimlinger, T. K., Haug, J., Kumar, S., Gonsalves, W. I., Vincent Rajkumar, S. & Kumar, S. K., Jan 1 2019, In : Haematologica. 104, 10, p. 2061-2074 14 p.

Research output: Contribution to journalArticle

Open Access
  • 3 Scopus citations

    Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma

    Painuly, U., Ramakrishnan, V., Kimlinger, T., Wellik, L., Haug, J., Gonsalves, W., Bi, L., Huang, Z., Rajkumar, S. V. & Kumar, S., Oct 1 2018, In : Oncotarget. 9, 77, p. 34582-34594 13 p.

    Research output: Contribution to journalArticle

  • 2 Scopus citations

    Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies

    Gonsalves, W. I., Ramakrishnan, V., Hitosugi, T., Ghosh, T., Jevremovic, D., Dutta, T., Sakrikar, D., Petterson, X. M., Wellik, L., Kumar, S. K. & Nair, K. S., Jan 11 2018, In : JCI Insight. 3, 1

    Research output: Contribution to journalArticle

    Open Access
  • 6 Scopus citations

    PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise

    Ramakrishnan, V. & Kumar, S. K., Jan 12 2018, (Accepted/In press) In : Leukemia and Lymphoma. p. 1-11 11 p.

    Research output: Contribution to journalArticle

  • 9 Scopus citations
  • 1 Scopus citations